Lung

LF/TERT309

Evercyte ́s human lung fibroblast cell line LF/TERT309 can be grown without limitations while maintaining expression of cell type specific markers and functions. Therefore, these cells are valuable as standardized in vitro model to study pulmonary function and pathophysiology such as airway inflammation and remodeling or production of extracellular matrix compounds.

Print Friendly, PDF & Email

from

€ 1300,–

LF/TERT309
Cat#: CHT-067-0309

ONLY FOR NON PROFIT

FOR PROFIT INDUSTRY

FOR PROFIT-CRO

Related Products

human adult skin fibroblasts HDF/TERT164

Related Services

Customer Reviews

“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”

 

Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.

“Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform.  We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed.”

Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.

hTERT immortalized, primary-like cells

get ready to standardize your cell culture work

news

Lecture on 3Rs

(replacement – reduction -refinement of animal experiments)

Related Products

human lung epithelial cells

HBEC3-KT

Related Services

interested in testing your compound for anti-fibrotic activity in vitro?

New document on

Good Cell Culture Practice 2.0

ALTEX 39(1), 030-070

Customer Reviews

“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”

 

Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.

“Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform.  We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed.”

Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.

Print Friendly, PDF & Email

from

€ 1300,–

LF/TERT309
Cat#: CHT-067-0309

ONLY FOR NON PROFIT

FOR PROFIT INDUSTRY

FOR PROFIT-CRO